Isha Preet Tuli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isha Preet Tuli has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Priyanka Chamoli
Department of ENT, VMMC and Safdarjung Hospital, New Delhi, India
3 shared publications - Sandeep Trehan
Department of Otorhinolaryngology and Head and Neck Surgery, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
3 shared publications - Shilpam Sharma
Department of ENT, VMMC and Safdarjung Hospital, New Delhi, India
3 shared publications - Sneha Nagendra
Department of Otorhinolaryngology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India
3 shared publications - Aashish Tomar
Vardhman Mahavir Medical College and Safdarjung Hospital, Department of Otorhinolaryngology and Head and Neck Surgery, New Delhi, India
2 shared publications - Bharti Gupta
Department of Ayurveda, Central Ayurveda Research Institute, New Delhi, India
2 shared publications
Latest Publications
- Open Access
- 25 September 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e56063
Ayurveda Management of Allergic Rhinitis: Protocol for a Randomized Controlled Trial
Background: Allergic rhinitis (AR) is the inflammation of the membranes lining the nose due to allergen exposure and is characterized by sneezing, nasal congestion, itching of the nose, or postnasal discharge. The prevalence varies worldwide, perhaps due to the geographic and aeroallergen differences, with 10% to 30% of the world’s population experiencing AR. In this study, Anu Taila Nasya, Naradiya Laxmivilas Rasa, and Shirishadi Kwath will be compared to a fluticasone nasal spray. Objective: The primary aim is to assess the efficacy of Ayurvedic management for AR (or vataja pratishyaya) by comparing it to a conventional control group. The secondary aims are to determine the mean change in the nasal endoscopy index and the mean change in the laboratory tests. Methods: This ongoing study is an open-label randomized controlled interventional trial, with a sample size of 90 both in the trial and standard control group (including dropouts, 20%), and will be carried out for 24 months. Participants in the trial group will receive Ayurvedic treatment, that is, Anu Taila Nasya (6 drops in each nostril for 7 days for 3 consecutive weeks), Naradiya Laxmivilas Rasa (250 mg twice per day), and Shirishadi Kwath (40 ml twice per day for 45 days). The participants in the control group will receive a fluticasone propionate nasal spray (2 sprays once per day for 45 days). The primary outcome will include the mean change in the Control of Allergic Rhinitis and Asthma Test score, and the secondary outcomes will include the mean change in the nasal endoscopy index (assessment of nasal membrane color, pale or hyperemia; rhinorrhea, watery or yellow; and inferior turbinate swelling, hypertrophy) and the mean change in the laboratory tests. Results: As of May 2024, 72 patients have been enrolled in both groups. Data analysis should be completed by February 2025. The study will be reported following standard guidelines for reporting randomized controlled trials. Clinical results will be disseminated through conferences and peer-reviewed publication in a relevant journal. Conclusions: The Ayurvedic approach could be an evidence-based therapeutic tactic for the management of AR. Trial Registration: Clinical Trials Registry India CTRI/2023/06/053395; https://tinyurl.com/564d2zz8 International Registered Report Identifier (IRRID): DERR1-10.2196/56063
- 25 September 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e56063
Open AccessAyurveda Management of Allergic Rhinitis: Protocol for a Randomized Controlled Trial
Background: Allergic rhinitis (AR) is the inflammation of the membranes lining the nose due to allergen exposure and is characterized by sneezing, nasal congestion, itching of the nose, or postnasal discharge. The prevalence varies worldwide, perhaps due to the geographic and aeroallergen differences, with 10% to 30% of the world’s population experiencing AR. In this study, Anu Taila Nasya, Naradiya Laxmivilas Rasa, and Shirishadi Kwath will be compared to a fluticasone nasal spray. Objective: The primary aim is to assess the efficacy of Ayurvedic management for AR (or vataja pratishyaya) by comparing it to a conventional control group. The secondary aims are to determine the mean change in the nasal endoscopy index and the mean change in the laboratory tests. Methods: This ongoing study is an open-label randomized controlled interventional trial, with a sample size of 90 both in the trial and standard control group (including dropouts, 20%), and will be carried out for 24 months. Participants in the trial group will receive Ayurvedic treatment, that is, Anu Taila Nasya (6 drops in each nostril for 7 days for 3 consecutive weeks), Naradiya Laxmivilas Rasa (250 mg twice per day), and Shirishadi Kwath (40 ml twice per day for 45 days). The participants in the control group will receive a fluticasone propionate nasal spray (2 sprays once per day for 45 days). The primary outcome will include the mean change in the Control of Allergic Rhinitis and Asthma Test score, and the secondary outcomes will include the mean change in the nasal endoscopy index (assessment of nasal membrane color, pale or hyperemia; rhinorrhea, watery or yellow; and inferior turbinate swelling, hypertrophy) and the mean change in the laboratory tests. Results: As of May 2024, 72 patients have been enrolled in both groups. Data analysis should be completed by February 2025. The study will be reported following standard guidelines for reporting randomized controlled trials. Clinical results will be disseminated through conferences and peer-reviewed publication in a relevant journal. Conclusions: The Ayurvedic approach could be an evidence-based therapeutic tactic for the management of AR. Trial Registration: Clinical Trials Registry India CTRI/2023/06/053395; https://tinyurl.com/564d2zz8 International Registered Report Identifier (IRRID): DERR1-10.2196/56063
- Open Access
- 15 February 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Ayurveda Management of Allergic Rhinitis: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Allergic rhinitis (AR) is the inflammation of the membranes lining the nose due to allergen exposure and is characterized by sneezing, nasal congestion, itching of the nose, or postnasal discharge. The prevalence varies worldwide, perhaps due to the geographic and aeroallergen differences, with 10% to 30% of the world’s population experiencing AR. In this study, Anu Taila Nasya, Naradiya Laxmivilas Rasa, and Shirishadi Kwath will be compared to a fluticasone nasal spray. OBJECTIVE The primary aim is to assess the efficacy of Ayurvedic management for AR (or vataja pratishyaya) by comparing it to a conventional control group. The secondary aims are to determine the mean change in the nasal endoscopy index and the mean change in the laboratory tests. METHODS This ongoing study is an open-label randomized controlled interventional trial, with a sample size of 90 both in the trial and standard control group (including dropouts, 20%), and will be carried out for 24 months. Participants in the trial group will receive Ayurvedic treatment, that is, Anu Taila Nasya (6 drops in each nostril for 7 days for 3 consecutive weeks), Naradiya Laxmivilas Rasa (250 mg twice per day), and Shirishadi Kwath (40 ml twice per day for 45 days). The participants in the control group will receive a fluticasone propionate nasal spray (2 sprays once per day for 45 days). The primary outcome will include the mean change in the Control of Allergic Rhinitis and Asthma Test score, and the secondary outcomes will include the mean change in the nasal endoscopy index (assessment of nasal membrane color, pale or hyperemia; rhinorrhea, watery or yellow; and inferior turbinate swelling, hypertrophy) and the mean change in the laboratory tests. RESULTS As of May 2024, 72 patients have been enrolled in both groups. Data analysis should be completed by February 2025. The study will be reported following standard guidelines for reporting randomized controlled trials. Clinical results will be disseminated through conferences and peer-reviewed publication in a relevant journal. CONCLUSIONS The Ayurvedic approach could be an evidence-based therapeutic tactic for the management of AR. CLINICALTRIAL Clinical Trials Registry India CTRI/2023/06/053395; https://tinyurl.com/564d2zz8 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/56063
- 15 February 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAyurveda Management of Allergic Rhinitis: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Allergic rhinitis (AR) is the inflammation of the membranes lining the nose due to allergen exposure and is characterized by sneezing, nasal congestion, itching of the nose, or postnasal discharge. The prevalence varies worldwide, perhaps due to the geographic and aeroallergen differences, with 10% to 30% of the world’s population experiencing AR. In this study, Anu Taila Nasya, Naradiya Laxmivilas Rasa, and Shirishadi Kwath will be compared to a fluticasone nasal spray. OBJECTIVE The primary aim is to assess the efficacy of Ayurvedic management for AR (or vataja pratishyaya) by comparing it to a conventional control group. The secondary aims are to determine the mean change in the nasal endoscopy index and the mean change in the laboratory tests. METHODS This ongoing study is an open-label randomized controlled interventional trial, with a sample size of 90 both in the trial and standard control group (including dropouts, 20%), and will be carried out for 24 months. Participants in the trial group will receive Ayurvedic treatment, that is, Anu Taila Nasya (6 drops in each nostril for 7 days for 3 consecutive weeks), Naradiya Laxmivilas Rasa (250 mg twice per day), and Shirishadi Kwath (40 ml twice per day for 45 days). The participants in the control group will receive a fluticasone propionate nasal spray (2 sprays once per day for 45 days). The primary outcome will include the mean change in the Control of Allergic Rhinitis and Asthma Test score, and the secondary outcomes will include the mean change in the nasal endoscopy index (assessment of nasal membrane color, pale or hyperemia; rhinorrhea, watery or yellow; and inferior turbinate swelling, hypertrophy) and the mean change in the laboratory tests. RESULTS As of May 2024, 72 patients have been enrolled in both groups. Data analysis should be completed by February 2025. The study will be reported following standard guidelines for reporting randomized controlled trials. Clinical results will be disseminated through conferences and peer-reviewed publication in a relevant journal. CONCLUSIONS The Ayurvedic approach could be an evidence-based therapeutic tactic for the management of AR. CLINICALTRIAL Clinical Trials Registry India CTRI/2023/06/053395; https://tinyurl.com/564d2zz8 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/56063
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
442. Unveiling Factors Associated with Mortality in Mucormycosis Patients: Insights from Second and Third Waves of COVID-19 Pandemic in India
Mucormycosis is one of the most aggressive opportunistic fungal infections. Though conventionally limited to the demographics of immunocompromised and those on the diabetes spectrum. It has recently propelled to the frontline in investigations of COVID-19 complications. For patients present in varied stages and severity of Mucormycosis, it's crucial to discuss the presenting factors that impact mortality in order to provide more intensive care and treatment from the beginning to those more at risk of death. All patients presenting to a tertiary care hospital in New Delhi, India with clinicopathological confirmed Mucormycosis were enrolled in the study. Detailed history and physical examination were performed, and a questionnaire of patient demographic details and comorbidities was filled out. There were 75 patients who met the inclusion criteria and were assessed after obtaining informed consent. Of these 75, 64 patients survived. The most common comorbidity in the study population was Diabetes spectrum(89.33%), followed by antecedent COVID-19 infection(64%) and hypertension(12%). Despite a high prevalence, none of these was significantly associated with mortality. The only comorbidity associated with mortality was Coronary Artery Disease(p-value< 0.05). The symptomatology at presentation was also assessed. Most commonly reported symptoms at presentation were Orbital/facial edema(45.33%), nasal discharge(29.33%), nasal block(29.33%) and diminution of vision(26.66%). The presence of proptosis at presentation in the patient was found to be significantly associated with a mortality outcome(p-value< .0.05). The glycemic control at presentation was also measured and compared between the survivors and non-survivors, however, no significant association was found. Mucormycosis patients with presenting symptoms of proptosis should be prognosticated early and managed in the intensive care unit from the beginning due to the increased risk of mortality. Also, patients with coronary artery disease should be similarly given special attention and care due to the association with mortality. Other factors like antecedent COVID-19, diabetes, hypertension, tobacco and alcohol use and the extent of hyperglycemia do not impact patient outcome All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access442. Unveiling Factors Associated with Mortality in Mucormycosis Patients: Insights from Second and Third Waves of COVID-19 Pandemic in India
Mucormycosis is one of the most aggressive opportunistic fungal infections. Though conventionally limited to the demographics of immunocompromised and those on the diabetes spectrum. It has recently propelled to the frontline in investigations of COVID-19 complications. For patients present in varied stages and severity of Mucormycosis, it's crucial to discuss the presenting factors that impact mortality in order to provide more intensive care and treatment from the beginning to those more at risk of death. All patients presenting to a tertiary care hospital in New Delhi, India with clinicopathological confirmed Mucormycosis were enrolled in the study. Detailed history and physical examination were performed, and a questionnaire of patient demographic details and comorbidities was filled out. There were 75 patients who met the inclusion criteria and were assessed after obtaining informed consent. Of these 75, 64 patients survived. The most common comorbidity in the study population was Diabetes spectrum(89.33%), followed by antecedent COVID-19 infection(64%) and hypertension(12%). Despite a high prevalence, none of these was significantly associated with mortality. The only comorbidity associated with mortality was Coronary Artery Disease(p-value< 0.05). The symptomatology at presentation was also assessed. Most commonly reported symptoms at presentation were Orbital/facial edema(45.33%), nasal discharge(29.33%), nasal block(29.33%) and diminution of vision(26.66%). The presence of proptosis at presentation in the patient was found to be significantly associated with a mortality outcome(p-value< .0.05). The glycemic control at presentation was also measured and compared between the survivors and non-survivors, however, no significant association was found. Mucormycosis patients with presenting symptoms of proptosis should be prognosticated early and managed in the intensive care unit from the beginning due to the increased risk of mortality. Also, patients with coronary artery disease should be similarly given special attention and care due to the association with mortality. Other factors like antecedent COVID-19, diabetes, hypertension, tobacco and alcohol use and the extent of hyperglycemia do not impact patient outcome All Authors: No reported disclosures
- 18 July 2021
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 74 (S2) , 3065-3071
Olfactory and Gustatory Dysfunctions in Patients With Laboratory-Confirmed COVID-19 Infection: A Change in the Trend
To study the presence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection in our set up. Longitudinal study, 1st March 2020-15th August 2020, at a tertiary care hospital. RT PCR positive for SARSCoV-2 patients, above 18 years age included. Excluding patients with previous history of changes in smell or taste sensation, severely ill at the time of admission, history of taking drugs at the time of COVID 19 infection that affect the smell or taste sensation. 435 patients included after obtaining an institutional ethical clearance. After an informed consent, these patients were followed up telephonically, to record any subjective improvement in olfactory or gustatory symptoms and an approximate duration of recovery. Olfactory and/or gustatory dysfunction 10.8% (47/435). Mean (SD) age—34.53(10.8) years. Females affected significantly more [X2 (1, N = 435) = 7.45, p value is 0.006, significant at p < 0.05]. Olfactory dysfunction significantly associated with gustatory dysfunction [X2 (1, n = 435) = 182.29, p < 0.00001]. 19.8% (N = 435) of individuals remained asymptomatic. Nasal symptoms rare (4%, N = 47). Mean (SD) recovery olfactory and gustatory dysfunction 12.1 (7.7) and10.8 (6.3) days respectively. Subjective loss of smell or taste dysfunction was far less common. Women and younger population reported olfactory or gustatory dysfunction commonly. Olfactory and gustatory changes without nasal symptoms, suspicion of COVID-19 infection is relevant. Recovery is complete and early.
- 18 July 2021
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 74 (S2) , 3065-3071
Olfactory and Gustatory Dysfunctions in Patients With Laboratory-Confirmed COVID-19 Infection: A Change in the Trend
To study the presence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection in our set up. Longitudinal study, 1st March 2020-15th August 2020, at a tertiary care hospital. RT PCR positive for SARSCoV-2 patients, above 18 years age included. Excluding patients with previous history of changes in smell or taste sensation, severely ill at the time of admission, history of taking drugs at the time of COVID 19 infection that affect the smell or taste sensation. 435 patients included after obtaining an institutional ethical clearance. After an informed consent, these patients were followed up telephonically, to record any subjective improvement in olfactory or gustatory symptoms and an approximate duration of recovery. Olfactory and/or gustatory dysfunction 10.8% (47/435). Mean (SD) age—34.53(10.8) years. Females affected significantly more [X2 (1, N = 435) = 7.45, p value is 0.006, significant at p < 0.05]. Olfactory dysfunction significantly associated with gustatory dysfunction [X2 (1, n = 435) = 182.29, p < 0.00001]. 19.8% (N = 435) of individuals remained asymptomatic. Nasal symptoms rare (4%, N = 47). Mean (SD) recovery olfactory and gustatory dysfunction 12.1 (7.7) and10.8 (6.3) days respectively. Subjective loss of smell or taste dysfunction was far less common. Women and younger population reported olfactory or gustatory dysfunction commonly. Olfactory and gustatory changes without nasal symptoms, suspicion of COVID-19 infection is relevant. Recovery is complete and early.
- Open Access
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (4) , 469-477
Diagnostic and therapeutic endonasal rhinologic procedures generating aerosol during COVID-19 pandemic: a systematized review
- 1 July 2021
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 87 (4) , 469-477
Open AccessDiagnostic and therapeutic endonasal rhinologic procedures generating aerosol during COVID-19 pandemic: a systematized review
- 10 March 2021
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 83 (S1) , 255-257
Spontaneous Subcutaneous Emphysema with Pneumothorax with Pneumomediastinum and Epidural Air with Spontaneous Resolution
- 10 March 2021
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 83 (S1) , 255-257
Spontaneous Subcutaneous Emphysema with Pneumothorax with Pneumomediastinum and Epidural Air with Spontaneous Resolution
- Open Access
- 3 March 2021
- Published by Knowledge E DMCC in Dubai Medical Journal
- Vol. 4 (1) , 77-80
Cricoid Ossification Mimicking an Esophageal Foreign Body: A Victim of Overdiagnosis
Laryngeal cartilages undergo ossification, usually after the third decade of life. Variations exist in the extent and age of onset of ossification. Radiologically, these ossified cartilages may mimic an aerodigestive tract foreign body. We present an unusual case where the ossified cricoid cartilage masqueraded as a fish bone in the aerodigestive tract. A 48-year-old male patient presented to us with a foreign body sensation and throat pain after consuming fish. We found no fish bone on endoscopic laryngopharyngeal assessment but noted a linear opacity against the C-6 vertebral body in the aerodigestive tract on a lateral X-ray film of the neck. Rigid esophagoscopy also did not reveal any foreign object, but a computed tomography (CT) scan showed a linear hyperdensity in the wall of the aerodigestive tract, against the C-6 vertebral body, due to linear ossification in the midline of the cricoid lamina posteriorly. The patient’s symptoms improved within 1 week of anti-reflux medications, and he remains asymptomatic. It is possible to encounter such rare cases of cartilage ossification while dealing with foreign body aerodigestive tract in adult patients in clinical practice. Proper assessment using CT scan prevents unnecessary procedures and anxiety to the patient.
- 3 March 2021
- Published by Knowledge E DMCC in Dubai Medical Journal
- Vol. 4 (1) , 77-80
Open AccessCricoid Ossification Mimicking an Esophageal Foreign Body: A Victim of Overdiagnosis
Laryngeal cartilages undergo ossification, usually after the third decade of life. Variations exist in the extent and age of onset of ossification. Radiologically, these ossified cartilages may mimic an aerodigestive tract foreign body. We present an unusual case where the ossified cricoid cartilage masqueraded as a fish bone in the aerodigestive tract. A 48-year-old male patient presented to us with a foreign body sensation and throat pain after consuming fish. We found no fish bone on endoscopic laryngopharyngeal assessment but noted a linear opacity against the C-6 vertebral body in the aerodigestive tract on a lateral X-ray film of the neck. Rigid esophagoscopy also did not reveal any foreign object, but a computed tomography (CT) scan showed a linear hyperdensity in the wall of the aerodigestive tract, against the C-6 vertebral body, due to linear ossification in the midline of the cricoid lamina posteriorly. The patient’s symptoms improved within 1 week of anti-reflux medications, and he remains asymptomatic. It is possible to encounter such rare cases of cartilage ossification while dealing with foreign body aerodigestive tract in adult patients in clinical practice. Proper assessment using CT scan prevents unnecessary procedures and anxiety to the patient.
- 17 February 2017
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 70 (3) , 331-336
Knowledge, Attitude of Sikkim Primary School Teachers About Paediatric Hearing Loss
Our purpose of the study was to assess the knowledge and any gaps of early educators regarding hearing impairment, and to attempt to delineate the attitudes and perceptions of the educators regarding the outcomes of their students with hearing disabilities and their views on inclusive teaching, using a questionnaire based study. Only 71 respondents completed the questionnaire. The present questionnaire based study was conducted on 100 primary school teachers, undertaken on randomly selected schools from Gangtok, East Sikkim. Their knowledge and attitudes regarding hearing impairment in children in the areas of cause, diagnosis, investigations, treatment, prevention, special care and inclusion into mainstream schools were assessed. Our study showed that the knowledge of causes, investigation and treatment of hearing impairement [HI] among respondents/teachers was poor. The data was shown statistically significant with P < 0.001. However, responses testing behavior and attitudes towards HI was encouraging. 52.9% respondents disagreed that HI was a social handicap and 88.2% felt that teachers need special training before a HI child is admitted to the school. The results were statistically significant with P < 0.001. The biggest obstacle found for inclusive education of HI children was a lack of proper training to teachers (40.8%) and attitude of other students (29.5%).
- 17 February 2017
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 70 (3) , 331-336
Knowledge, Attitude of Sikkim Primary School Teachers About Paediatric Hearing Loss
Our purpose of the study was to assess the knowledge and any gaps of early educators regarding hearing impairment, and to attempt to delineate the attitudes and perceptions of the educators regarding the outcomes of their students with hearing disabilities and their views on inclusive teaching, using a questionnaire based study. Only 71 respondents completed the questionnaire. The present questionnaire based study was conducted on 100 primary school teachers, undertaken on randomly selected schools from Gangtok, East Sikkim. Their knowledge and attitudes regarding hearing impairment in children in the areas of cause, diagnosis, investigations, treatment, prevention, special care and inclusion into mainstream schools were assessed. Our study showed that the knowledge of causes, investigation and treatment of hearing impairement [HI] among respondents/teachers was poor. The data was shown statistically significant with P < 0.001. However, responses testing behavior and attitudes towards HI was encouraging. 52.9% respondents disagreed that HI was a social handicap and 88.2% felt that teachers need special training before a HI child is admitted to the school. The results were statistically significant with P < 0.001. The biggest obstacle found for inclusive education of HI children was a lack of proper training to teachers (40.8%) and attitude of other students (29.5%).